- Recently, Cardinal Health reported another earnings beat on EPS despite a slight revenue miss, and was highlighted for its role in the expanding neonatal intensive care respiratory devices market, which is projected to reach about US$5.70 billion by 2035.
- This combination of consistent earnings outperformance and exposure to a growing neonatal respiratory segment is reinforcing investor interest in Cardinal Health’s broader healthcare distribution and products platform.
- We’ll now examine how this ongoing earnings momentum, particularly the recent EPS outperformance, may influence Cardinal Health’s existing investment narrative.
AI is about to change healthcare. These 39 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
Cardinal Health Investment Narrative Recap
To own Cardinal Health, you need to believe its scale in pharmaceutical and medical product distribution can keep translating into resilient earnings, even as regulation and competition remain persistent threats. The recent EPS beat, despite a slight revenue miss, supports that resilience in the short term, but it does not materially reduce longer term concerns about margin pressure from government pricing scrutiny and tariffs.
Among recent announcements, the continued share repurchases under the multi year buyback plan stand out alongside the earnings surprise. For investors focused on near term catalysts, the combination of EPS outperformance and ongoing capital returns may reinforce the existing narrative that Cardinal’s core distribution and products platform can support shareholder returns, even while the neonatal respiratory opportunity and other growth areas are still developing.
Yet, against that backdrop of momentum, the risk that tighter government pricing and reimbursement changes could pressure margins is something investors should be aware of...
Read the full narrative on Cardinal Health (it's free!)
Cardinal Health's narrative projects $314.4 billion revenue and $2.3 billion earnings by 2029. This requires 7.8% yearly revenue growth and roughly a $0.7 billion earnings increase from $1.6 billion today.
Uncover how Cardinal Health's forecasts yield a $245.27 fair value, a 3% upside to its current price.
Exploring Other Perspectives
Four Simply Wall St Community fair value estimates for Cardinal Health span roughly US$190 to about US$466 per share, underscoring how far apart individual views can be. When you set those opinions against the risk of long term margin pressure from regulation and tariffs, it becomes even more important to weigh several perspectives on how Cardinal’s earnings power might hold up.
Explore 4 other fair value estimates on Cardinal Health - why the stock might be worth as much as 96% more than the current price!
The Verdict Is Yours
Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.
- A great starting point for your Cardinal Health research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision.
- Our free Cardinal Health research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Cardinal Health's overall financial health at a glance.
Curious About Other Options?
Every day counts. These free picks are already gaining attention. See them before the crowd does:
- Capitalize on the AI infrastructure supercycle with our selection of the 51 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
- The future of work is here. Discover the 29 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
- Invest in the nuclear renaissance through our list of 89 elite nuclear energy infrastructure plays powering the global AI revolution.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com